Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer-Reference-Cited by-同舟云学术

Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer

Published:2020-09 Issue: Volume:137 Page:148-160
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Teufel Andreas,Gerken Michael,Fürst Alois,Ebert Matthias,Hohenthanner Ina,Klinkhammer-Schalke Monika

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;Andre;N Engl J Med,2004

2. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer;de Gramont;J Clin Oncol,2000

3. Chemotherapy for stage II colon cancer;Varghese;Clin Colon Rectal Surg,2015

4. Adjuvant chemotherapy for stage II colon cancer: the debate goes on;Lee;J Oncol Pract,2017

5. Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer;Teufel;BMC Canc,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?;Medicina;2024-08-22

2. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023);Clinical and Translational Oncology;2024-06-24

3. Clinical, pathological, and adjuvant chemotherapy use differences among microsatellite unstable and microsatellite stable colon cancers;Journal of the National Cancer Center;2024-06

4. The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program;Human Pathology;2024-04

5. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC;Clinical Cancer Research;2024-02-29